Clinical Trials Logo

HER-2 Positive Gastric Cancer clinical trials

View clinical trials related to HER-2 Positive Gastric Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01396707 Completed - Clinical trials for Her-2 Positive Gastric Cancer

Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX

Start date: June 2011
Phase: Phase 2
Study type: Interventional

This is an open-label, multicentre, prospective phase II trial designed to evaluate the efficacy and safety of trastuzumab in combination with capecitabine and oxaliplatin as first-line therapy in patients with recurrent and/or metastatic HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction.